ACR Congress Review 2019
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
etween January 2008 and December 2015. Among 10,442 patients identified, 36.5% swapped to a<br />
non-TNFi drug, most commonly abatacept (54.2%). The remaining 63.5% switched to a cycling regimen<br />
(second TNFi), most commonly adalimumab (41.2%). For subsequent lines of therapy, non-TNFi drugs<br />
were more common. Patients who swapped were significantly older and sicker than those who cycled<br />
(P
Change language